Aptamers Are Fastest Growing Segment Fueling The Growth Of The Global Aptamers Market
Aptamers Market |
Market Overview:
Aptamers are short, single-stranded DNA or RNA ligands that can bind to and modulate the activity of target molecules ranging from small chemicals to biological macromolecules and cells. They are typically produced through an in vitro selection process called SELEX. Aptamers offer advantages over antibodies as they are chemically synthesized and exhibit high binding affinity and specificity.
Market key trends:
Growing research and development activities in aptamer-based technologies is expected to drive the aptamers market growth over the forecast period. For instance, aptamers have applications not only as affinity reagents and diagnostics but also as therapeutic agents. Nucleic acid aptamers can bind specifically and with high affinity to various molecular targets and are considered alternatives to monoclonal antibodies. They offer advantages of smaller size, easy modification, non-immunogenicity, high stability and relatively low production costs.
The global Aptamers Market Share is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights
Segment Analysis
The global aptamers market is segmented on the basis of type, technology, application, and end user. Based on type, the market is segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The RNA-based aptamers segment currently dominates the market as RNA aptamers exhibit high affinity and specificity for target molecules. Based on technology, the market is classified into SELEX, X-aptamer technology, MODIFYing immobilization SELEX (MODASELEX), and others. SELEX technology holds the largest share as it is the gold standard technique for aptamer generation and selection.
Key Takeaways
The global aptamers market is expected to witness high growth, exhibiting CAGR of 18% over the forecast period, due to increasing R&D investments for development of aptamer-based therapeutics. Regionally, North America is expected to dominate the global market over the forecast period. This is owing to presence of major market players and technological advancements in the region. Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.
The global aptamers market size is expected to reach USD 6265.49 Mn by 2023. Regionally, North America is expected to grow at the highest CAGR during the forecast period due to rising healthcare expenditure and presence of major market players in the region. Europe is also expected to show considerable growth owing to the increased R&D funding for development of aptamer-based therapeutics.
Key players operating in the aptamers market include Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Major players are focusing on new product launches, collaborations and mergers & acquisitions to gain market share.
Read More: https://www.pressreleasebulletin.com/the-global-aptamers-market-growth-trends-and-forecast-analysis/
Comments
Post a Comment